Syneron Medical Ltd (ELOS)

[midastouch017]

Syneron Announces Preliminary Results for 2005

Tuesday January 3, 7:00 am ET

Preliminary Results Show Revenue Increased More Than 50% in 2005

YOKNEAM, ISRAEL--(MARKET WIRE)--Jan 3, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News) today announced that for the year ended December 31, 2005, preliminary results indicate revenues of approximately $88 million, a greater than 50% increase from 2004. This recognized revenue does not include $3-4 million that were invoiced and shipped, but not delivered due to logistical holiday limitations preventing the delivery and/or acceptance of deliveries during the abbreviated holiday week at the end of the last quarter.

For Q4 2005, while preliminary results showed recognized revenue of approximately $24 million, invoicing and shipments totaled over $27 million.

Commenting on the results, Syneron CEO David Schlachet said, "Since assuming the role of CEO in the second half of the fourth quarter, I have worked intensely with our sales teams worldwide to meet our sales targets. We have reorganized the structure of the North American sales force in a direction that we believe will increase further the efficiency of the organization over the long term. Our organization now consists of 45 salespeople in North America, organized in seven territories each with a dedicated regional manager. Previously, our North American sales team was grouped into only four territories which had become too cumbersome for each regional manager to lead effectively."

Conference call

Syneron Management will host a conference call to discuss the preliminary results 9:00am ET today, January 3, 2006. Investors and other interested parties may access a live webcast through Syneron's web site at www.syneron.com. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company's web site.

About Syneron

Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elos(TM), the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

http://biz.yahoo.com/iw/060103/0105076.html

Israel's Syneron says 2005 revenue rose 50 pct
Tue Jan 3, 2006 07:13 AM ET
Jan 3 (Reuters) - Syneron Medical Ltd. (ELOS.O: Quote, Profile, Research) on Tuesday said according to its preliminary results, revenue for 2005 rose more than 50 percent from the previous year.
The Israeli company, in a news release said it expects revenue of about $88 million for 2005, excluding $3 million to $4 million that were invoiced and shipped, but not delivered.

For the fourth quarter, Syneron's recognized revenue was about $24 million, while invoicing and shipments totaled over $27 million, it said. (Reporting by Tuhin Kar in Bangalore)

http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh11828_2006-01-03_12-13-18_wna...

Dubi